Heng Tang

1.1k total citations
32 papers, 899 citations indexed

About

Heng Tang is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Heng Tang has authored 32 papers receiving a total of 899 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 9 papers in Cancer Research and 8 papers in Oncology. Recurrent topics in Heng Tang's work include Advanced biosensing and bioanalysis techniques (5 papers), Chemotherapy-induced cardiotoxicity and mitigation (5 papers) and RNA modifications and cancer (4 papers). Heng Tang is often cited by papers focused on Advanced biosensing and bioanalysis techniques (5 papers), Chemotherapy-induced cardiotoxicity and mitigation (5 papers) and RNA modifications and cancer (4 papers). Heng Tang collaborates with scholars based in China, United States and Taiwan. Heng Tang's co-authors include Shuang Peng, Binglin Bie, Hexiang Deng, Peng Pu, Min Liu, Qiancheng Song, Xiaodong Feng, Xiang Zhou, Hengjiang Cong and Yangzesheng Sun and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Nucleic Acids Research.

In The Last Decade

Heng Tang

31 papers receiving 890 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Heng Tang China 16 466 188 136 127 108 32 899
Ge‐Bo Wen China 20 807 1.7× 98 0.5× 115 0.8× 198 1.6× 143 1.3× 72 1.3k
Shuxia Liu China 24 650 1.4× 166 0.9× 204 1.5× 225 1.8× 149 1.4× 73 1.5k
Yin Ji China 17 461 1.0× 143 0.8× 223 1.6× 143 1.1× 62 0.6× 42 1.0k
Zhijun Ge China 18 418 0.9× 56 0.3× 175 1.3× 117 0.9× 162 1.5× 46 835
Jinxin Che China 19 484 1.0× 158 0.8× 151 1.1× 91 0.7× 199 1.8× 80 966
Shanshan Liu China 17 491 1.1× 116 0.6× 84 0.6× 174 1.4× 117 1.1× 39 886
Alessandra Valentini Italy 20 598 1.3× 73 0.4× 92 0.7× 94 0.7× 417 3.9× 34 1.2k
Shuang Deng China 19 606 1.3× 75 0.4× 146 1.1× 308 2.4× 121 1.1× 51 1.3k
Jianmiao Liu France 24 533 1.1× 62 0.3× 59 0.4× 119 0.9× 160 1.5× 38 1.5k
Wangshu Zhu China 11 364 0.8× 198 1.1× 271 2.0× 58 0.5× 83 0.8× 15 838

Countries citing papers authored by Heng Tang

Since Specialization
Citations

This map shows the geographic impact of Heng Tang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heng Tang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heng Tang more than expected).

Fields of papers citing papers by Heng Tang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heng Tang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heng Tang. The network helps show where Heng Tang may publish in the future.

Co-authorship network of co-authors of Heng Tang

This figure shows the co-authorship network connecting the top 25 collaborators of Heng Tang. A scholar is included among the top collaborators of Heng Tang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heng Tang. Heng Tang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jiang, Zhiming, Ningfeng Zhu, Donghui Wang, et al.. (2025). Exploring the multi-targeted mechanism of Saikosaponin A in prostate cancer treatment: a network pharmacology and molecular docking approach. Frontiers in Pharmacology. 16. 1530715–1530715. 2 indexed citations
2.
Tang, Heng, Jie Yang, Xin Jiang, et al.. (2025). Enhanced or reversible RNA N6-methyladenosine editing by red/far-red light induction. Nucleic Acids Research. 53(5). 3 indexed citations
3.
4.
Shi, Hongwei, Lian Duan, Peng Pu, et al.. (2024). Research Progress on Flavonoids in Traditional Chinese Medicine to Counteract Cardiotoxicity Associated with Anti-Tumor Drugs. Reviews in Cardiovascular Medicine. 25(3). 74–74. 5 indexed citations
5.
6.
Tang, Heng, Xin Jiang, Shuang Peng, et al.. (2023). A CRISPR-Cas and Tat Peptide with Fluorescent RNA Aptamer System for Signal Amplification in RNA Imaging. Biosensors. 13(2). 293–293. 4 indexed citations
7.
Sun, Yuqing, Haixin Yu, Shaoqing Han, et al.. (2023). Method for the extraction of circulating nucleic acids based on MOF reveals cell-free RNA signatures in liver cancer. National Science Review. 11(1). nwae022–nwae022. 8 indexed citations
8.
Shi, Hongwei, et al.. (2023). RING Finger Protein 10 Regulates AP-1/Meox2 to Mediate Pirarubicin-Induced Cardiomyocyte Apoptosis. Oxidative Medicine and Cellular Longevity. 2023. 1–11. 2 indexed citations
9.
Xiao, Feng, Haomiao Su, Hui Liu, et al.. (2022). Inert Pepper aptamer-mediated endogenous mRNA recognition and imaging in living cells. Nucleic Acids Research. 50(14). e84–e84. 32 indexed citations
10.
Shi, Hongwei, Yue Yan, Hong Yang, Peng Pu, & Heng Tang. (2022). Schisandrin B Diet Inhibits Oxidative Stress to Reduce Ferroptosis and Lipid Peroxidation to Prevent Pirarubicin‐Induced Hepatotoxicity. BioMed Research International. 2022(1). 5623555–5623555. 19 indexed citations
11.
Tang, Heng, et al.. (2021). The ‘diamond’ approach to personalized drug treatment of heart failure with reduced ejection fraction. Reviews in Cardiovascular Medicine. 22(3). 573–584.
12.
Shi, Hongwei, Heng Tang, Wen Ai, et al.. (2021). Schisandrin B Antagonizes Cardiotoxicity Induced by Pirarubicin by Inhibiting Mitochondrial Permeability Transition Pore (mPTP) Opening and Decreasing Cardiomyocyte Apoptosis. Frontiers in Pharmacology. 12. 733805–733805. 34 indexed citations
13.
Shi, Hongwei, Qingfu Zeng, Yun‐Jie Wei, et al.. (2021). Canagliflozin is a potential cardioprotective drug but exerts no significant effects on pirarubicin‑induced cardiotoxicity in rats. Molecular Medicine Reports. 24(4). 10 indexed citations
14.
Tang, Heng, et al.. (2021). Kaempferide improves oxidative stress and inflammation by inhibiting the TLR4/IκBα/NF-κB pathway in obese mice.. SHILAP Revista de lepidopterología. 24(4). 493–498. 13 indexed citations
15.
Gao, Lingyun, Heng Tang, Qingfu Zeng, et al.. (2020). The anti-insulin resistance effect of scutellarin may be related to antioxidant stress and AMPKα activation in diabetic mice. Obesity Research & Clinical Practice. 14(4). 368–374. 26 indexed citations
16.
Meng, Rui, Heng Tang, Huimin Wang, et al.. (2019). Design of a liver cancer‑specific selector for the analysis of circulating tumor DNA. Oncology Letters. 17(6). 5369–5376. 1 indexed citations
17.
Liu, Yuan, et al.. (2018). Acupuncture therapy for the treatment of stable angina pectoris: An updated meta-analysis of randomized controlled trials. Complementary Therapies in Clinical Practice. 34. 247–253. 28 indexed citations
18.
Feng, Xiaodong, et al.. (2015). Receptor-interacting protein kinase 3 is a predictor of survival and plays a tumor suppressive role in colorectal cancer. Neoplasma. 62(4). 592–601. 141 indexed citations
19.
Mousa, Shaker A., Hung‐Yun Lin, Heng Tang, et al.. (2014). Modulation of angiogenesis by thyroid hormone and hormone analogues: implications for cancer management. Angiogenesis. 17(3). 463–469. 57 indexed citations
20.
Davis, Paul J., Gennadi V. Glinsky, Hung‐Yun Lin, et al.. (2013). Molecular Mechanisms of Actions of Formulations of the Thyroid Hormone Analogue, Tetrac, on the Inflammatory Response. Endocrine Research. 38(2). 112–118. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ge‐Bo Wen Breakdown of academic impact, for papers by Shuxia Liu Breakdown of academic impact, for papers by Yin Ji Breakdown of academic impact, for papers by Zhijun Ge Breakdown of academic impact, for papers by Jinxin Che Breakdown of academic impact, for papers by Shanshan Liu Breakdown of academic impact, for papers by Alessandra Valentini Breakdown of academic impact, for papers by Shuang Deng Breakdown of academic impact, for papers by Jianmiao Liu Breakdown of academic impact, for papers by Wangshu Zhu
Rankless by CCL
2026